Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2014, Article ID 367564, 7 pages
http://dx.doi.org/10.1155/2014/367564
Clinical Study

Factors Associated with Utilization of Dipeptidyl-4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Retrospective Study

1Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
2Clinical Investigation Centre, Faculty of Medicine, University Malaya Medical Centre, 13th Floor Main Tower, 59100 Lembah Pantai, Kuala Lumpur, Malaysia
3Endocrinology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia

Received 14 July 2014; Accepted 21 August 2014; Published 2 September 2014

Academic Editor: Ilias Migdalis

Copyright © 2014 Hasniza Zaman Huri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. International Diabetes Federation, IDF Diabetes Atlas Update 2012, 2012, http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf.
  2. International Diabetes Federation, 2012, http://www.idf.org/types-diabetes.
  3. Ministry of Health Malaysia, The Future of Diabetes in Malaysia, Malaysian Diabetes Educators Society Seminar, 2012.
  4. Pharmaceutical Services Division and the Clinical Research Centre, “Malaysian Statistics on Medicine,” 2007, http://www.pharmacy.gov.my/v2/sites/default/files/document-upload/msom2007.pdf.
  5. American Diabetes Association, “Standard of medical care in diabetes,” Diabetes Care, vol. 36, no. 1, pp. S11–S66, 2013. View at Google Scholar
  6. H. Duez, B. Cariou, and B. Staels, “DPP-4 inhibitors in the treatment of type 2 diabetes,” Biochemical Pharmacology, vol. 83, no. 7, pp. 823–832, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Pathak and M. B. Bridgeman, “Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes,” Pharmacy and Therapeutics, vol. 35, no. 9, pp. 509–513, 2010. View at Google Scholar · View at Scopus
  8. Malaysian Dia betes Association, “A New Approach to Type 2 Diabetes Drug Treatment is Now Available in Malaysia,” 2007, http://www.diabetes.org.my/article.php?aid=202.
  9. Ministry of Health Malaysia, Drug Formulary, Ministry of Health Malaysia, 2013.
  10. A. J. Bergman, J. Cote, B. Yi et al., “Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor,” Diabetes Care, vol. 30, no. 7, pp. 1862–1864, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Mafauzy, “Diabetes control and complications in public hospitals in Malaysia,” Medical Journal of Malaysia, vol. 61, no. 4, pp. 477–483, 2006. View at Google Scholar · View at Scopus
  12. M. Eid, M. Mafauzy, and A. R. Faridah, “Glycaemic control of type 2 diabetic patients on follow up at Hospital Universiti Sains Malaysia,” The Malaysian Journal of Medical Sciences, vol. 10, no. 2, pp. 40–49, 2003. View at Google Scholar · View at Scopus
  13. M. Mafauzy, Z. Hussein, and S. P. Chan, “The status of diabetes control in Malaysia: results of DiabCare 2008,” Medical Journal of Malaysia, vol. 66, no. 3, pp. 175–181, 2011. View at Google Scholar · View at Scopus
  14. B. H. Chew, I. Mastura, P. Y. Lee et al., “Ethnic differences in glycaemic control and complications: the adult diabetes control and management (ADCM), Malaysia,” Medical Journal of Malaysia, vol. 66, no. 3, p. 245, 2011. View at Google Scholar
  15. J. E. Shaw, R. A. Sicree, and P. Z. Zimmet, “Global estimates of the prevalence of diabetes for 2010 and 2030,” Diabetes Research and Clinical Practice, vol. 87, no. 1, pp. 4–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Mafauzy, “Diabetes control and complications in private primary healthcare in Malaysia,” Medical Journal of Malaysia, vol. 60, no. 2, pp. 212–217, 2005. View at Google Scholar · View at Scopus
  17. Malaysian Ministry of Healt, “National Health Morbidity Survey IV Kuala Lumpur,” Institute of Public Health Malaysia, 2012.
  18. Ministry of Health Malaysia, Malaysian Society of Hypertension, and Academy of Medicine, Clinical Practice Guideline. “Management of Hypertension”, Ministry of Health Malaysia, Kuala Lumpur, Malaysia, 3rd edition, 2008.
  19. I. Truter, “An investigation into antidiabetic medication prescribing in South Africa,” Journal of Clinical Pharmacy and Therapeutics, vol. 23, no. 6, pp. 417–422, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. C. H. Po and A. Todd, “Drug utilization review of dipeptidyl peptidase-4 (DPP-4) inhibitors in Alice Ho Miu Ling Nethersole Hospital (AHNH),” in Proceedings of the Hong Kong Pharmacy Conference, 2012.
  21. B. Ahrén, “Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin—diabetes control and potential adverse events,” Best Practice & Research: Clinical Endocrinology & Metabolism, vol. 23, no. 4, pp. 487–498, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. Ministry of Health Malaysia/Malaysian Endocrine & Metabolic Society/Academy of Medicine & Malaysian Diabetes Association: Clinical Practice Guideline, Management of Type 2 Diabetes Mellitus, Ministry of Health Malaysia, Kuala Lumpur, Malaysia, 4th edition, 2009.
  23. A. Khalam, C. Dilip, and C. Shinu, “Drug use evaluation of diabetes mellitus in hospitalized patients of a tertiary care referral hospital,” Journal of Basic and Clinical Physiology and Pharmacology, vol. 23, no. 4, pp. 173–177, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. National Institute for Health and Clinical Excellence (NICE), Type 2 Diabetes: The Management of Type 2 Diabetes, 2009, http://www.nice.org.uk/nicemedia/pdf/CG66NICEGuideline.pdf.
  25. S. L. Schwartz, “Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors,” The American Journal Geriatric Pharmacotherapy, vol. 8, no. 5, pp. 405–418, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Wai, L. G. Kearney, D. L. Hare, M. Ord, L. M. Burrell, and P. M. Srivastava, “Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control,” Cardiovascular Diabetology, vol. 11, no. 1, pp. 1–5, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. Ministry of Health Malaysia, Malaysian Society for The Study of Obesity Clinical Practice Guideline, Management of Obesity Ministry of Health Malaysia, Kuala Lumpur, Malaysia, 2004.
  28. Ministry of Health Malaysia, and National Heart Association of Malaysia & Academy of Medicine, Clinical Practice Guideline: Management of Dyslipidemia (4th Ed), Ministry of Health Malaysia, Kuala Lumpur, Malaysia, 2011.
  29. World Health Organization & International Diabetes Association, Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus, WHO, Geneva, Switzerland, 2011.